Table 3.
Colorectal cancer cohort.
| Characteristics | Progression-free survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable models | Multivariable model | Univariable models | Multivariable model | |||||
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Sex | 0.242 | 0.228 | ||||||
| Male | Ref. | Ref. | ||||||
| Female | 0.92 (0.79–1.06) | 0.90 (1.11–0.77) | ||||||
| Age, years | 0.446 | 0.601 | ||||||
| <70 | Ref. | Ref. | ||||||
| ⩾70 | 1.07 (0.90–1.27) | 1.17 (0.97–1.41) | ||||||
| ECOG PS | <0.001 | <0.001 | <0.001 | <0.001 | ||||
| 0 | Ref. | Ref. | Ref. | Ref. | ||||
| ⩾1 | 1.65 (1.38–1.97) | 1.57 (1.30–1.88) | 1.84 (1.52–2.23) | 1.88 (1.54–2.29) | ||||
| Primary tumour resection | 0.003 | 0.006 | <0.001 | 0.014 | ||||
| No | Ref. | Ref. | Ref. | Ref. | ||||
| Yes | 0.81 (0.71–0.93) | 0.82 (0.71–0.95) | 0.76 (0.65–0.89) | 0.80 (0.68–0.96) | ||||
| Site of origin | 0.049 | 0.002 | <0.001 | <0.001 | ||||
| Right | Ref. | Ref. | Ref. | Ref. | ||||
| Left | 0.86 (0.74–0.99) | 0.79 (0.68–0.92) | 0.71 (0.60–0.84) | 0.68 (0.57–0.81) | ||||
| Synchronous mets | 0.107 | 0.01 | 0.459 | |||||
| No | Ref. | Ref. | Ref. | |||||
| Yes | 1.18 (0.96–1.45) | 1.37 (1.08–1.74) | 1.11 (0.85–1.44) | |||||
| Liver mets | 0.008 | 0.001 | 0.003 | <0.001 | ||||
| No | Ref. | Ref. | Ref. | Ref. | ||||
| Yes | 1.26 (1.06–1.49) | 1.34 (1.13–1.60) | 1.36 (1.11–1.66) | 1.50 (1.21–1.87) | ||||
| Nodal mets | 0.537 | 0.034 | 0.041 | |||||
| No | Ref. | Ref. | Ref. | |||||
| Yes | 1.05 (0.90–1.22) | 1.20 (1.01–1.42) | 1.20 (1.01–1.43) | |||||
| Lung mets | <0.001 | <0.001 | <0.001 | <0.001 | ||||
| No | Ref. | Ref. | Ref. | Ref. | ||||
| Yes | 1.28 (1.11–1.48) | 1.35 (1.17–1.57) | 1.33 (1.13–1.57) | 1.46 (1.23–1.72) | ||||
| RAS status | 0.234 | 0.058 | ||||||
| Wild-type | Ref. | Ref. | ||||||
| Mutated | 1.06 (0.96–1.17) | 1.11 (0.99–1.24) | ||||||
| BRAF status | 0.094 | <0.001 | 0.016 | |||||
| Wild-type | Ref. | Ref. | Ref. | |||||
| Mutated | 1.10 (0.98–1.22) | 1.24 (1.10–1.40) | 1.16 (1.03–1.31) | |||||
| MSS status | 0.247 | 0.401 | ||||||
| MSS | Ref. | Ref. | ||||||
| MSI | 1.05 (0.97–1.15) | 1.04 (0.94–1.15) | ||||||
| Chemotherapy | 0.002 | 0.001 | 0.282 | |||||
| Doublet | Ref. | Ref. | Ref. | |||||
| Triplet | 0.79 (0.69–0.92) | 0.78 (0.68–0.91) | 0.91 (0.77–1.08) | |||||
| Biologic agent | 0.724 | 0.022 | 0.726 | |||||
| Bevacizumab | Ref. | Ref. | Ref. | |||||
| Panitumumab | 0.97 (0.83–1.14) | 0.81 (0.67–0.97) | 0.96 (0.79–1.18) | |||||
| PM | 0.007 | <0.001 | <0.001 | 0.006 | ||||
| No PM | Ref. | Ref. | Ref. | Ref. | ||||
| PM without ascites | 1.10 (0.91–1.34) | 1.14 (0.93–1.39) | 1.04 (0.84–1.30) | 1.10 (0.88–1.38) | ||||
| PM with ascites | 1.68 (1.21–2.35) | 1.60 (1.14–2.24) | 2.14 (1.57–3.01) | 1.78 (1.26–2.51) | ||||
Cox proportional hazards regression models for both progression-free survival and overall survival. Both univariable and multivariable model outcomes are shown.
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; MSI, microsatellite instability; MSS, microsatellite stability; PM, peritoneal metastases.